cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Biomarin Pharmaceutical Inc
49 own
25 watching
Current Price
$84.56
$-1.03
(-1.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
15,875.2M
52-Week High
52-Week High
99.56000
52-Week Low
52-Week Low
73.68000
Average Volume
Average Volume
1.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
965.9684
iconMarket Capitalization15,875.2M
icon52-Week High99.56000
icon52-Week Low73.68000
iconAverage Volume1.03M
iconDividend Yield--
iconP/E Ratio965.9684
What does the Biomarin Pharmaceutical Inc do?
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Read More
How much money does Biomarin Pharmaceutical Inc make?
News & Events about Biomarin Pharmaceutical Inc.
TipRanks Financial Blog
1 year ago
In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on BioMarin Pharmaceutical (BMRN Research R... In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on BioMarin Pharmaceutical (BMRN &#8211...
Zolmax
1 year ago
BioMarin Pharmaceutical (NASDAQ:BMRN Get Rating) had its price objective decreased by Guggenheim from $125.00 to $120.00 in a report published on Thursday morning, The Fly reports. Other equities research analysts have also recently issued reports about the stock. Oppenheimer cut shares of BioMarin ...
Ticker Report
1 year ago
AIA Group Ltd lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN Get Rating) by 168.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,313 shares of the biotechnology companys stock after ...
Zolmax
1 year ago
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN Get Rating) CEO Jean Jacques Bienaime sold 10,000 shares of the companys stock in a transaction dated Thursday, April 6th. The stock was sold at an average price of $96.13, for a total transaction of $961,300.00. Following the completion of the transaction, ...
PR Newswire
1 year ago
BioMarin Provides Update on FDA Review of ROCTAVIAN (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A BioMarin Provides Update on FDA Review of ROCTAVIAN (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A PR Newswire SAN RAFAEL, Calif., March...
Frequently Asked Questions
Frequently Asked Questions
What is Biomarin Pharmaceutical Inc share price today?
plus_minus_icon
Can Indians buy Biomarin Pharmaceutical Inc shares?
plus_minus_icon
How can I buy Biomarin Pharmaceutical Inc shares from India?
plus_minus_icon
Can Fractional shares of Biomarin Pharmaceutical Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Biomarin Pharmaceutical Inc stocks?
plus_minus_icon
What is today’s traded volume of Biomarin Pharmaceutical Inc?
plus_minus_icon
What is today’s market capitalisation of Biomarin Pharmaceutical Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Biomarin Pharmaceutical Inc?
plus_minus_icon
What percentage is Biomarin Pharmaceutical Inc down from its 52-Week High?
plus_minus_icon
What percentage is Biomarin Pharmaceutical Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$84.56
$-1.03
(-1.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$319.70
$4.53 (1.44 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$495.26
$3.00 (0.61 %)
United Therapeutics Corporation
United Therapeutics Corporation
$338.32
$1.95 (0.58 %)
Bio-Techne Corp.
Bio-Techne Corp.
$80.65
$1.98 (2.52 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$319.70
$4.53 (1.44 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$495.26
$3.00 (0.61 %)
United Therapeutics Corporation
United Therapeutics Corporation
$338.32
$1.95 (0.58 %)
Bio-Techne Corp.
Bio-Techne Corp.
$80.65
$1.98 (2.52 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00